Boehringer's anti-clotting drug Pradaxa gains EU approval

08/4/2011 | Reuters

The European Commission approved Boehringer Ingelheim's Pradaxa for preventing stroke in people with atrial fibrillation. The approval underscores Boehringer's lead over other drugmakers in replacing anticoagulant warfarin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ